Northwell Health

The Clinical Impact of Early Detection of Extended-Spectrum Beta Lactamase (ESBL) Bacteremia in Hospitalized Patients, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, November 18, 2022
Adult, GN, Northwell Health, Mortality, ESBL, Length of stay, Patient, Doctor of Pharmacy, BCID, Microbiology, Pathology, Subclinical infection, Culture, Hospital, patients, health, territories, Food, Vaccine, Pharmaceutical industry, Medicine, Pharmacy, Bloodstream infections

TORONTO, Nov. 18, 2022 /PRNewswire-PRWeb/ -- With the recent improvements of molecular blood culture identification (BCID) panels, time to pathogen and resistance profile identification generated from a positive blood culture has been drastically reduced. Compared to conventional culture and antibiotic susceptibility testing, this rapid turnaround allows the microbiology lab to deliver results to the clinical teams more efficiently to allow for prompt administration of the correct regimen of antibiotics and antifungals. More specifically when looking at gram-negative (GN) pathogens, organisms harboring extended-spectrum beta-lactamases (ESBL), can be reported within three hours after a blood culture turns positive and the molecular test, inclusive of genotypic resistance genes, such as CTX-M, can be reported out at Northwell Health Laboratories. Until now, the clinical impact remained unclear.

Key Points: 
  • Attendees will take a closer look at the improvements that can be made by implementing rapid molecular diagnostics for bloodstream infections.
  • The featured speaker will dive further into how results from rapid diagnostics for bloodstream infections can impact overall therapeutic interventions in a healthcare system.
  • Register to learn about the clinical impact of early detection of ESBL bacteremia in hospitalized patients.
  • For more information, or to register for this event, visit The Clinical Impact of Early Detection of Extended-Spectrum Beta Lactamase (ESBL) Bacteremia in Hospitalized Patients .

Research Revolution Conference, Powered by Florence Healthcare, Tackles Slowdown in Drug Development Due to Trial Site Stress

Retrieved on: 
Thursday, November 10, 2022
Research, Technology, Clinical Trials, Cardiology, Software, General Health, Pharmaceutical, Health, Data Management, Science, Hospital, Business, Northwell Health, Contract, Food, Research, Travel, Academic health science centre, Technology, Clinical research, Degenerative disease, Sitelink, Pharmacy, Food and Drug Administration, Cros, Senior, Cancer, BIPOC, Woman, Conference, Patient, Health literacy, Industry, Pharmaceutical industry, Medical device

As a result, research sites, sponsors, Contract Research Organizations (CROs), technology vendors, and patient advocates must collaborate to run clinical trials more efficiently.

Key Points: 
  • As a result, research sites, sponsors, Contract Research Organizations (CROs), technology vendors, and patient advocates must collaborate to run clinical trials more efficiently.
  • To solve the capacity gap in clinical research, we need to enable research sites to do their best work, says Florence Healthcare CEO Ryan Jones.
  • Research Revolution confirmed that everyone in clinical research has a common goal: bringing cures to more patients, more efficiently, said Jones.
  • Florence Healthcares clinical trial software helps more than 10,000 research sites in 45 countries manage their documents, data, and workflows.

Northwell Holdings and Aegis Ventures Sign Strategic Collaboration Agreement to Launch Upliv, a Comprehensive Digital Health Company for Menopause

Retrieved on: 
Thursday, November 10, 2022
Well, Aegis, Northwell Health, Love, Health, European Menopause and Andropause Society, Hofstra University, Health care, Women's health, Menopause, Intelligence, Holding, Weight gain, Intention, Flash, Total, Neurology, Psychiatry, Fatigue, Practitioner, Brain, NAMS, Patient, Myalgia, Solution, Time, Senior, Nursing, Gaps, Life, Woman, North American Menopause Society, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Cardiology, National Board of Health and Welfare (Sweden), Health insurance, Cryptocurrency, Pharmaceutical industry, Medicine, Management

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Northwell Holdings and Aegis Ventures inked an agreement today for the formation of Upliv, a women's virtual care start-up that aims to raise the bar for clinical menopause support. Upliv will partner with employers to offer virtual telemedicine services and whole-person care to employees experiencing perimenopause and menopause symptoms. Initially, Upliv will offer services to select nurses through a pilot program at Northwell Health, followed by an expected enterprise-wide rollout in the first quarter of 2023.

Key Points: 
  • Upliv is the joint creation of Aegis Ventures and Northwell Holdings, the for-profit investment arm of Northwell Health.
  • In April 2022, Aegis Ventures announced the intention to invest at least $100 million in seed-stage funds towards the development of joint ventures with Northwell Health.
  • Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies.
  • Through strategic partnerships, Holdings leverages the health system's robust enterprise data assets to develop AI-enabled solutions that address healthcare inequities.

Feinstein Institutes’ Valentin Pavlov Elected President of the International Society for Autonomic Neuroscience

Retrieved on: 
Wednesday, November 9, 2022
General Health, Other Health, Health, Science, Research, Digestion, Autonomic nervous system, Rheumatoid arthritis, Northwell Health, Pulmonary hypertension, Feinstein Institute for Medical Research, Heart rate, Leadership, Doctor of Philosophy, 3D, ISAN, Vagus nerve, International Society, International Society for Autonomic Neuroscience, Diabetes, Respiration, Communication, Knowledge, Research, NIH, Multimedia, Mental health, Credit, Genetics, Neuron, Brain, Medicine, Injury, Molecular medicine, Biomedical engineering, Inflammation, Cancer, Arthritis, Science, Disorder, Neuroscience, Medical research, Patient, Inflammatory Bowel Diseases, Autoimmunity, Crohn's disease, CEO, Feinstein, Infection, DRS, Blood pressure, Paralysis, Metabolism, Congress, Medical device, Dentistry, Pharmaceutical industry, MD

The International Society for Autonomic Neuroscience (ISAN) has elected The Feinstein Institutes for Medical Research's Valentin Pavlov, PhD , as president in recognition of his dedication and research of the brain and autonomic nervous system, particularly in the regulation of inflammation and metabolism.

Key Points: 
  • The International Society for Autonomic Neuroscience (ISAN) has elected The Feinstein Institutes for Medical Research's Valentin Pavlov, PhD , as president in recognition of his dedication and research of the brain and autonomic nervous system, particularly in the regulation of inflammation and metabolism.
  • View the full release here: https://www.businesswire.com/news/home/20221109005208/en/
    Dr. Valentin Pavlov is a professor at the Feinstein Institutes Institute of Bioelectronic Medicine.
  • It is a privilege and honor to take up the mantle of president for the International Society for Autonomic Neuroscience.
  • Dr. Pavlov's election to president of the International Society for Autonomic Neuroscience is timely evidence of his leadership in bioelectronic medicine, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research.

New Digital Tool Dramatically Reduces Blood Clot Risk During and Post-Hospital Care, Feinstein Institutes Study Shows

Retrieved on: 
Monday, November 7, 2022
COVID-19, Research, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Diagnosis, Health information management, American Heart, VTE, Medicine, S-1 Executive Committee, Feinstein Institute for Medical Research, Physician, Thrombosis, Institute, Hospital, Patient, Credit, CDS, Technology, Decision-making, Medical research, Infection, Cancer, EHR, Clinical trial, Executive Committee, ATE, Method, Genetics, Embolism, COVID-19, Late, Stroke, AHA, MIS, Feinstein, Digital technology, Mental health, Science, Northwell Health, Research, Autoimmunity, Multimedia, Risk, Molecular medicine, Health, CEO, Pharmaceutical industry, Medical device, MD

View the full release here: https://www.businesswire.com/news/home/20221107005864/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221107005864/en/
    Dr. Alex Spyropoulos research shows a better way to conduct patient care for those who are suffering from blood clots.
  • (Credit: Feinstein Institutes)
    Dr. Spyropoulos is a world-renowned expert in blood clots who shared critical COVID-19 research during the height of the pandemic.
  • Using the IMPROVE-DD VTE score, doctors can prescribe the appropriate thromboprophylaxis for patients at moderate and high risk of blood clots.
  • The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.

Feinstein Institutes Bioelectronic Medicine Researchers Target Specific Vagus Nerve Fibers for More Precise, Effective Stimulation

Retrieved on: 
Friday, November 4, 2022
Research, Surgery, Medical Devices, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, Science, Doctor of Philosophy, Medical research, Hertz, SPARC, Neuroscience, Research, Science, Map, Lupus, Multimedia, Human, Mouse, Brain stimulation, Brain, Heart rate, Feinstein Institute for Medical Research, National, Rheumatoid arthritis, Vagus nerve stimulation, Condition, Inflammation, Mental health, Anatomy, Vagus nerve, Genetics, CEO, Credit, VNS, Nerve, Reflex, Medicine, Cough, Northwell Health, Autoimmunity, Vocal cords, Diabetes, Disease, Biomedical engineering, NIH, Molecular medicine, Cancer, RATS, Medical device, Pharmaceutical industry, MD

A new paper published in Brain Stimulation showed that delivering high-frequency electrical stimulation activates specific sensory nerve fibers of the vagus nerve and could be the key to better targeting and treating inflammation and disease.

Key Points: 
  • A new paper published in Brain Stimulation showed that delivering high-frequency electrical stimulation activates specific sensory nerve fibers of the vagus nerve and could be the key to better targeting and treating inflammation and disease.
  • View the full release here: https://www.businesswire.com/news/home/20221104005611/en/
    Dr. Stavros Zanos recently led the study, which targets specific fibers in the vagus nerve for more precise electrical stimulation.
  • (Credit: Feinstein Institutes)
    The research study, led by Stavros Zanos, MD, PhD , associate professor at the Feinstein Institutes Institute of Bioelectronic Medicine , measured how vagus nerve stimulation (VNS) using kHz stimulation an electrical stimulus that is commonly used to block nerve conduction at over 1,000 pulses per second affects the activity of different types of vagal fibers.
  • Previous VNS therapies would stimulate the whole nerve bluntly, without targeting specific fibers, which could cause adverse effects and less effective therapy.

Medical Device Venture Lazzaro Medical Secures $1M from Northwell Heath

Retrieved on: 
Thursday, October 27, 2022
Feinstein Institute for Medical Research, Medicine, International trade, Cartilage, Nursing, TBM, Medical research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, MITR, COPD, Disease, Economic development, FDA, Instagram, Patient, LinkedIn, National Institute of Advanced Industrial Science and Technology, Awareness, CDO, Entrepreneurship, CEO, Hospital, Trachea, Patent, Physician, Twitter, Safety, Medical device, Pharmaceutical industry, Tracheobronchomalacia, Facebook, Northwell Health

BOULDER, Colo., Oct. 27, 2022 /PRNewswire-PRWeb/ -- Lazzaro Medical, a Boulder-based medical device company seeking to help millions of people suffering from Tracheobronchomalacia (TBM), received a $1 million strategic investment from Northwell Health, New York State's largest healthcare provider.

Key Points: 
  • BOULDER, Colo., Oct. 27, 2022 /PRNewswire-PRWeb/ -- Lazzaro Medical , a Boulder-based medical device company seeking to help millions of people suffering from Tracheobronchomalacia (TBM), received a $1 million strategic investment from Northwell Health, New York State's largest healthcare provider.
  • Previous treatment was worse than the disease for many potential patients," said Dr. Lazzaro, Co-Founder and Chief Medical Officer of Lazzaro Medical.
  • "We're thrilled to welcome this strategic investment from Northwell, a world-class leader driving innovation in patient outcomes and care," saidRob Israel, Co-Founder and CDO of Lazzaro Medical.
  • For more information on Lazzaro Medical, please visit Lazzaromed.com , or follow @Lazzaro Medical on LinkedIn .

Feinstein Institutes Awarded $6.7M From NIH to Create First Human Vagus Nerve Anatomical Map

Retrieved on: 
Wednesday, October 26, 2022
Research, Science, Knowledge, Method, LinkedIn, Heart rate, Disease, Medicine, Nerve, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Rheumatoid arthritis, Science, Anatomy, Neck, Data analysis, Medical research, Esophagus, Research, NIH, Program, VNS, Multimedia, Feinstein Institute for Medical Research, Abdomen, Extrapyramidal system, Artificial intelligence, Cancer, Inflammation, Mental health, Feinstein, Immune system, Molecular medicine, Doctor of Philosophy, REVA, Health, Data & Analysis Center for Software, National, CEO, Liver, Diabetes, Autoimmunity, Temple University, Condition, Genetics, Maintenance, Brain, Northwell Health, SPARC, Metabolism, Heart, Homeostasis, Map, Institute, DAVE, Credit, Digestion, Vagus nerve, Algorithm, Medical device, Medical imaging, MD

(Credit: Feinstein Institutes)

Key Points: 
  • (Credit: Feinstein Institutes)
    The landmark funding is part of the NIH Common Funds Stimulating Peripheral Activity to Relieve Conditions (SPARC) program .
  • How sensory and motor fibers are arranged inside the vagus nerve and pathways to different organs are essentially unknown.
  • The vagus nerve, which means wandering in Latin, runs from the brainstem to most of the bodys major organs.
  • Through the use of electrical stimulation of the vagus nerve (VNS), researchers at the Feinstein Institutes and elsewhere try to reset vagus nerve activity and fight inflammation.

Feinstein Institutes, Northwell electrophysiologist successfully implant first modular cardiac rhythm management system in novel clinical trial

Retrieved on: 
Friday, October 21, 2022
Health, Medical Devices, Surgery, Health Technology, Clinical Trials, Cardiology, Biotechnology, Physician, LinkedIn, Communication, Risk, Medicine, CRM, Population, Science, Arrest, Medical research, MPS, Patient, Research, Multimedia, Feinstein Institute for Medical Research, Mental health, Electrophysiology, EMPOWER, Cancer, Emergency department, Molecular medicine, Subcutaneous Implantable Defibrillator (S-ICD), Laurence, Autoimmunity, Genetics, Clinical trial, Shock, Nursing, Cardiac arrest, Northwell Health, ATP, North Shore University Hospital, Heart, Death, Perspiration, Credit, Coma, Medical device, Boston Scientific, MD

Like a paramedic in your chest, a team of Northwell Health clinicians, electrophysiologists and clinical trial investigators at The Feinstein Institutes for Medical Research successfully implanted a modular cardiac rhythm management (CRM) system in the first patient to be enrolled in the Boston Scientific MODULAR ATP clinical trial.

Key Points: 
  • Like a paramedic in your chest, a team of Northwell Health clinicians, electrophysiologists and clinical trial investigators at The Feinstein Institutes for Medical Research successfully implanted a modular cardiac rhythm management (CRM) system in the first patient to be enrolled in the Boston Scientific MODULAR ATP clinical trial.
  • View the full release here: https://www.businesswire.com/news/home/20221021005348/en/
    Laurence M. Epstein, MD (center right) implanted the first patient in Boston Scientifics MODULAR ATP clinical trial at North Shore University Hospital.
  • The trial will also investigate the system and procedure-related complication-free rate of the EMPOWER MPS.
  • The MODULAR ATP trial will enroll up to 60 centers in the U.S., Canada and Europe up to 300 patients.

Feinstein Institutes urges areas of focus to improve preventative lung cancer screenings

Retrieved on: 
Friday, October 14, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, LinkedIn, Risk, Medicine, Prevalence, Science, Gaps, Implementation, Smoking, Person, Medical research, Patient, American Indians, Research, Multimedia, Feinstein Institute for Medical Research, Â, Mental health, Internal medicine, Institute, Lung cancer, Cancer, Annals of Internal Medicine, Molecular medicine, Doctor of Philosophy, Health, Donald, CEO, Ageing, Autoimmunity, Genetics, Alaska Natives, USPSTF, Northwell Health, Credit, Medical imaging, MD

Approximately 130,000 people will die from lung cancer in 2022, making it the most common cause of cancer death in the United States.

Key Points: 
  • Approximately 130,000 people will die from lung cancer in 2022, making it the most common cause of cancer death in the United States.
  • View the full release here: https://www.businesswire.com/news/home/20221014005372/en/
    Karina Davidson, PhD, is the director of the Institute of Health System Science at the Feinstein Institutes.
  • (Credit: Feinstein Institutes for Medical Research)
    To address the growing lung cancer crisis in 2014, the U.S. Preventative Services Task Force (USPSTF) expanded lung cancer screening guidelines for certain people.
  • Dr. Davidsons thoughtful review of current lung cancer screening guidelines and gaps that should be addressed is timely and important.